Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L Neville

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
The Urologic Clinics of North America|September 14, 2000
Wilms' tumor. Overview of National Wilms' Tumor Study Group resultsH L Neville, M L Ritchey
Palliative Medicine|October 7, 2003
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemiaH l Neville-Webbe, R E Coleman
European Journal of Cancer (Oxford, England : 1990)|March 30, 2010
Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone diseaseH L Neville-Webbe, R E Coleman
Journal of Pediatric Surgery|May 17, 2000
Emergent abdominal decompression with patch abdominoplasty in the pediatric patientH L Neville, K P Lally, C S Cox
British Journal of Cancer|February 18, 2010
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionH L Neville-Webbe, R E Coleman, I Holen
Cancer Treatment Reviews|December 10, 2002
The anti-tumour activity of bisphosphonatesH L Neville-Webbe, I Holen, R E Coleman
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 15, 2006
Magnesium depletion in patients receiving cisplatin-based chemotherapyE Hodgkinson, H L Neville-Webbe, R E Coleman
Oncology (Williston Park, N.Y.)|December 1, 2000
Multidisciplinary management of pediatric soft-tissue sarcomaH L Neville, R B Raney, R J Andrassy, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 4, 2006
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitroH L Neville-Webbe, C A Evans, R E Coleman, et al.
Current Pharmaceutical Design|February 20, 2010
Targeting RANK/RANKL in the treatment of solid tumours and myelomaC H Buckle, H L Neville-Webbe, P I Croucher, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Urologic Clinics of North America|September 14, 2000
Wilms' tumor. Overview of National Wilms' Tumor Study Group resultsH L Neville, M L Ritchey
Palliative Medicine|October 7, 2003
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemiaH l Neville-Webbe, R E Coleman
European Journal of Cancer (Oxford, England : 1990)|March 30, 2010
Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone diseaseH L Neville-Webbe, R E Coleman
Journal of Pediatric Surgery|May 17, 2000
Emergent abdominal decompression with patch abdominoplasty in the pediatric patientH L Neville, K P Lally, C S Cox
British Journal of Cancer|February 18, 2010
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionH L Neville-Webbe, R E Coleman, I Holen
Cancer Treatment Reviews|December 10, 2002
The anti-tumour activity of bisphosphonatesH L Neville-Webbe, I Holen, R E Coleman
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 15, 2006
Magnesium depletion in patients receiving cisplatin-based chemotherapyE Hodgkinson, H L Neville-Webbe, R E Coleman
Oncology (Williston Park, N.Y.)|December 1, 2000
Multidisciplinary management of pediatric soft-tissue sarcomaH L Neville, R B Raney, R J Andrassy, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 4, 2006
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitroH L Neville-Webbe, C A Evans, R E Coleman, et al.
Current Pharmaceutical Design|February 20, 2010
Targeting RANK/RANKL in the treatment of solid tumours and myelomaC H Buckle, H L Neville-Webbe, P I Croucher, et al.
Pageof 2